SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
RAPT Therapeutics, Inc. (RAPT) .
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($30.71, 47.1%).
- Analyst consensus target $30.71 (-47.1% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 24/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RAPT
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.19
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$30.71 (-47.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-2.01 |
$0.00 |
$-29.12M |
- |
| 2018 |
$-2.09 |
$0.00 |
$-36.15M |
- |
| 2019 |
$-1.97 |
$0.00 |
$-43M |
- |
| 2020 |
$-2.19 |
$5.04M |
$-52.89M |
-1049% |
| 2021 |
$-2.49 |
$3.81M |
$-68.21M |
-1788.8% |
| 2022 |
$-2.52 |
$1.53M |
$-81.88M |
-5362.2% |
| 2023 |
$-3.05 |
$0.00 |
$-116.8M |
- |
| 2024 |
$-3.19 |
$0.00 |
$-129.87M |
- |
